Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Ovarian Cancer – Current Treatment – Current Treatment: Physician Insights – Ovarian Cancer (US)

Login to access report north_east
Contact sales account_box

Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing decisions. The use of Lynparza (AstraZeneca / Merck & Co.), Zejula (GlaxoSmithKline), and Rubraca (Pharma&) as maintenance therapy across multiple lines and biomarker-defined patient populations is creating new sequencing dynamics. Elahere, set to be the standard of care for FRα-positive patients, is having an impact on the treatment algorithm for platinum-resistant disease.

Questions answered

  • What is the patient share of key therapies for advanced-stage ovarian cancer by line of therapy?
  • What factors influence physicians’ choice of first-line maintenance treatment (e.g., Lynparza plus bevacizumab versus Zejula) for advanced-stage ovarian cancer?
  • What are the key drivers of and barriers to the use of select drugs for advanced-stage ovarian cancer?
  • How do drug-treatment rates vary between key ovarian cancer patient populations, according to stage of disease and line of therapy?

Markets covered: United States

Primary research: Survey of 100 U.S. medical oncologists fielded in April 2024

Key drugs: bevacizumab, Lynparza, Zejula, Rubraca, and Elahere

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
north_east
Report
Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…
north_east
Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east